FY2024 Earnings Forecast for Pfizer Issued By Zacks Research

Pfizer Inc. (NYSE:PFE) – Equities researchers at Zacks Research raised their FY2024 EPS estimates for shares of Pfizer in a research report issued on Monday, November 18th. Zacks Research analyst K. Shah now anticipates that the biopharmaceutical company will post earnings per share of $2.87 for the year, up from their prior forecast of $2.57. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share. Zacks Research also issued estimates for Pfizer’s Q2 2026 earnings at $0.63 EPS, Q3 2026 earnings at $0.78 EPS and FY2026 earnings at $2.94 EPS.

Other research analysts have also issued reports about the stock. Barclays lifted their price objective on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Sanford C. Bernstein began coverage on shares of Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target for the company. UBS Group increased their price objective on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $32.92.

Pfizer Price Performance

Shares of Pfizer stock opened at $25.06 on Wednesday. The stock has a 50 day moving average price of $28.28 and a 200-day moving average price of $28.58. Pfizer has a one year low of $24.48 and a one year high of $31.54. The stock has a market cap of $142.03 billion, a price-to-earnings ratio of 33.87, a price-to-earnings-growth ratio of 0.80 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. During the same quarter last year, the business posted ($0.17) earnings per share. The firm’s revenue was up 31.2% on a year-over-year basis.

Institutional Trading of Pfizer

A number of institutional investors have recently made changes to their positions in PFE. Olistico Wealth LLC acquired a new stake in Pfizer in the second quarter worth about $25,000. MFA Wealth Advisors LLC purchased a new position in shares of Pfizer in the 2nd quarter valued at approximately $29,000. Gladius Capital Management LP boosted its stake in Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 38,015 shares in the last quarter. Quarry LP purchased a new stake in Pfizer during the 2nd quarter worth approximately $31,000. Finally, Financial Connections Group Inc. acquired a new position in Pfizer during the 2nd quarter valued at approximately $34,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Buying and Selling

In other news, Director Scott Gottlieb bought 1,000 shares of the stock in a transaction on Wednesday, October 30th. The stock was bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is currently owned by company insiders.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.70%. The ex-dividend date is Friday, November 8th. Pfizer’s payout ratio is 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.